GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong

TESARO, a subsidiary of GSK plc (LSE/NYSE: GSK), has announced an update regarding its ongoing legal dispute with AnaptysBio, Inc.

The Delaware Chancery Court granted AnaptysBio’s motion to dismiss TESARO’s claim for anticipatory breach. This decision does not impact TESARO’s remaining claim for declaratory judgment.

GSK and TESARO maintain their stance that AnaptysBio’s allegations are without merit and will continue to pursue their claim at trial. The litigation stems from allegations by AnaptysBio that TESARO has not met certain requirements of their March 2014 license agreement related to dostarlimab, leading AnaptysBio to consider revoking TESARO’s license.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Despite the legal challenge, Jemperli (dostarlimab), continues to demonstrate robust growth. The drug is approved in over 35 countries for specific endometrial cancers, the most prevalent form of gynecologic cancer in the United States. GSK and TESARO have reported significant growth for Jemperli, fueled by label expansions in both the US and EU.

A comprehensive clinical trial program is underway, evaluating the potential use of dostarlimab in additional cancers, including rectal, colon, and head and neck cancers. This expansion strategy underscores GSK’s commitment to maximizing the therapeutic potential of Jemperli.

Driver Breakdown:

• Label Expansion: Approvals for use in specific endometrial cancers in the US and EU are driving revenue growth.
• Clinical Trials: Ongoing trials targeting additional cancers signal potential for future revenue streams.
• Global Reach: Approved in over 35 countries, Jemperli has a significant international market presence.

The focus remains on the core dispute and the potential impact on the dostarlimab license. The drug’s commercial success, particularly with ongoing label expansions and clinical trials, is a crucial factor for investors to consider.